RAMONA BOYD: Open Payments
NPI 1871815316 · LEBANON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,193 in 71 payments from 13 companies in 2025. Trend: 2023 $412 · 2024 $1,076 · 2025 $2,193
Food & beverage: $2,193
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $589 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $412 |
| ABBVIE INC. | 16 | $336 |
| Abbott Laboratories | 4 | $170 |
| Neurocrine BioSciences, Inc. | 3 | $149 |
| Axsome Therapeutics, Inc. | 3 | $142 |
| Novo Nordisk Inc | 8 | $135 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| KYOWA KIRIN, INC. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
Products named: AIRSUPRA, CAPLYTA, QULIPTA, FREESTYLE LIBRE 3, INGREZZA, Auvelity, BREZTRI, VRAYLAR.
Industry payments across VA — which companies pay providers there.
